{"title": "PDF", "author": "PDF", "url": "https://www.kssg.ch/system/files/media_document/2019-11/Sulz_Medikament%C3%B6seTherapie%20bei%20Morbus%20Crohn.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Medikament\u00f6se   \nTherapie  bei  \nMorbus Crohn  Viszeralmedizinische  Fortbildung   \n20.11.2019  \nPD Dr. med. Michael Sulz  \nLeitender Arzt  \nStv. Leiter Fachbereich IBD  \nKlinik f\u00fcr Gastroenterologie und Hepatologie  - 1 - Morbus Crohn: Eine  \nchronisch entz\u00fcndliche Darmerkrankung  \n-Erstbeschreibung 1932 durch Burrill  Crohn  \nCrohn BB et al.  JAMA  1932  -\u00c4tiologie noch immer unklar, immunvermittelt  \n \n-Krankheit des jungen Menschen  - 1 - Morbus Crohn: Eine  \nchronisch entz\u00fcndliche Darmerkrankung  \n-\u00c4tiologie noch immer unklar, immunvermittelt  \n \n-Krankheit des jungen Menschen  -Erstbeschreibung 1932 durch Burrill  Crohn  \n-Segmental, h\u00e4ufig im terminalen Ileum  \n \n-Transmural  (ganze Darmwand betreffend)  \n \n-H\u00e4ufig komplizierter Verlauf:  \n    Entz\u00fcndung \uf0e0 Stenose \uf0e0 Fisteln  \nMedikament\u00f6se \nTherapie  Krankheits -\nprogression  \n Therapie - \nkonzept  \nHeraus - \nforderungen   \nTherapie -\nAlgorithmus  \n(endo -\nluminal )  Vedolizumab  \nund \nUstekinumab  Emerging \ntherapies  Postoperative  \nTherapie  Take home   \nmessages  Agenda  Window of  \nopportunity  Hospitalisations  Delay in \ntreatment  Bowel damage  \n(L\u00e9mann score)  \nCDAI, Crohn\u2019s Disease Activity Index; CDEIS, Crohn\u2019s Disease Endoscopic Index of Severity; CRP, C -reactive protein; GI, gastroin testinal.  \nFigure adapted from Colombel  JF et al. Gastroenterology. 2017;152:351 -61.  Progression und inflammatorische  Aktivit\u00e4t  Age at diagnosis   \n A1 below  16 y \n A2 between  17 and 40 y \n A3 above  40 y  \n \n  \nLocation   \n L1 ileal \n L2 colonic  \n L3 ileo-colonic  \n L4 isolated  upper  disease * \n Behavior   \n B1 non\u2010 stricturing , non\u2010 penetrating  \n B2 stricturing  \n B3 penetrating  \n p   perianal  disease  modifier  * Montreal classification   \n* can be added  \nSatsangi  J, et al. Gut. 2006 Jun;55(6):749 -53. \nIndicator  \nYoung age at diagnosis  \nCorticoid steroids necessary at time of diagnosis  \nEarly stricturing  or penetrating disease (B2 and/or B3)  \nIleal or ileocolonic disease location (L1 or L3)  \nRectal disease  \nSevere upper gastrointestinal disease (L4)  \nPerianal disease  \nSevere endoscopic lesions  \nSmoking  \nPositive antimicrobial markers  \nNOD2 -mutation (risk for ileal disease /risk of surgery)  Indikatoren f\u00fcr Krankheitsprogression/schweren Verlauf  \nTorres J, et al. Lancet. 2017 Apr 29;389(10080):1741 -1755.  Beaugerie  L, et al. Gastroenterology . 2006 Mar;130(3):650 -6. Therapiekonzept  Lokalisation  \nKrankheits -\nverhalten  \nKomor -\nbidit\u00e4ten  \nExtra -\nintestinale \nMani -\nfestationen  Alter des \nPatienten  Fr\u00fchere \nTherapien  Patienten -\ncompliance  Einstellung \ndes \nPatienten  Multifaktorielles Therapiemanagement  \n \nGASTROENTEROLOGE  CHIRURG  RADIOLOGE  Herausforderungen bleiben\u2026 trotz anti -TNF Blockern  \n\u2022Prim\u00e4res Nicht -Ansprechen 20 -40%  \n Herausforderungen bleiben\u2026 trotz anti -TNF Blockern  \n\u2022Prim\u00e4res Nicht -Ansprechen 20 -40%  \n \n\u2022Wirkverlust 23 -46% 1 \n \n1 Ben -Horin  S, et al. Autoimmun Rev. 2014 Jan;13(1):24 -30. \n Herausforderungen bleiben\u2026 trotz anti -TNF Blockern  \n\u2022Prim\u00e4res Nicht -Ansprechen 20 -40%  \n \n\u2022Wirkverlust 23 -46% 1 \n \n\u2022Anti-TNF induzierte Psoriasis ca. 5% 2, seltener lupus -like syndrome   \n \n1 Ben -Horin  S, et al. Autoimmun Rev. 2014 Jan;13(1):24 -30. \n2 Tillack  C, et al. Gut. 2014 Apr;63(4):567 -77.  \n Herausforderungen bleiben\u2026 trotz anti -TNF Blockern  \n\u2022Prim\u00e4res Nicht -Ansprechen 20 -40%  \n \n\u2022Wirkverlust 23 -46% 1 \n \n\u2022Anti-TNF induzierte Psoriasis ca. 5% 2, seltener lupus -like syndrome   \n \n\u2022Zunehmend \u00e4ltere Patienten, vermehrt Ko -Morbidit\u00e4ten  \n \n\u2022Problem bei Patienten mit Malignom -Anamnese  \n1 Ben -Horin  S, et al. Autoimmun Rev. 2014 Jan;13(1):24 -30. \n2 Tillack  C, et al. Gut. 2014 Apr;63(4):567 -77.  \n Algorithm1: EndoluminalCD(withoutfistula)12,21,27,28,30-34\n% Budesonide:  CortimentMMX  isnot approvedfortreatmentofCD\n# See Table 1  (Indicatorsforseveredisease/ diseaseprogression)\n&Anti-TNF: Tumor-necrosis-factoralphaantibodies: Infliximabanditsbiosimilars(Remicade\u00ae/Inflectra\u00ae/Remsima\u00ae); Adalimumab(Humira\u00ae/Hyrimoz\u00ae); \nCertolizumabPeglol(Cimzia\u00ae).Response /Remission\nNoresponse/noremission/recurrence- Ileo-cecal: Budesonide%\n- Mesalazine(> 2..4 g/day)  \nasalternative  optionModerate toseveredisease Patientswith\nhigh riskfor\ndisease\nprogression#\nIfindicated,  in \nselectedpatients:\nNomedicationMaintain\nremissionwith\nAZA/6-MP/  \nMTXSteroid-dependent:\nTaperingofsteroidswithin16 \nweeksimpossibleorrecurrence\nwithin12 weeksafter stopping\nsteroidsSteroid-refractory:  \nActivediseasedespiteoral \ncorticosteroidsduring4weeks\nSurgerytobe\ndiscussed\n(especiallyin \nlocalizedileo-\ncecaldisease)Anti-Integrin\nVedolizumab\n(preferin elder-\nlies and/orhx\nofmalignancy)Anti-TNF&\n+/\u2013\nAZA/6-MP/ MTX \n(preferCombo-therapy, \nifpossible)\nInsufficientresponse\norlossofresponseIntoleranceor\nprimarynon response\n1.Optimizebyescalation(dose escalation\nor/andintervalreduction)\n2.Add AZA/6-MP, ifCombo possibleChange tootheranti-\nTNF&ortoother\nclassofbiologicals3. Change tootherclass\nofbiologicalsSurgerytobe\nevaluatedMaintain\nremissionwith\nselectedagentAssessment ofresponseafter 2 weeks; Tapering\nofcorticosteroids\nAssessment ofresponse\nevery10\u201312weeks\nAssessment ofresponse\nevery10-12 weeksAssessment ofresponseevery10-12 weeks(symptoms, calprotectinandUS) \n+ Antibiotics, \nifindicated\nAnti-TNFfirstchoice, especiallyifEIM presentand/or\nfasterresponsenecessary\nAnti-IL12/23\nUstekinumab\n(preferin selected\ncaseswithco-\nexistent psoriasis)In general: secondchoiceSystemiccorticosteroids\n+/\u2013\nAZA/6-MP/MTXMild diseaseEndoluminaler  M. Crohn: Therapie -Algorithmus  \n\u00a9Michael Sulz  Sulz MC, et al. submitted  to Digestion (Nov 2019)  \nAZA Azathioprine  \nEIM Extra -intestinal  manifestations  \nIL Interleukin   \n6-MP 6-mercaptopurin   \nMTX   Methotrexate  \nTNF Tumour  necrosis  factor  \nUS Ultrasonography   Algorithm1: EndoluminalCD(withoutfistula)12,21,27,28,30-34\n% Budesonide:  CortimentMMX  isnot approvedfortreatmentofCD\n# See Table 1  (Indicatorsforseveredisease/ diseaseprogression)\n&Anti-TNF: Tumor-necrosis-factoralphaantibodies: Infliximabanditsbiosimilars(Remicade\u00ae/Inflectra\u00ae/Remsima\u00ae); Adalimumab(Humira\u00ae/Hyrimoz\u00ae); \nCertolizumabPeglol(Cimzia\u00ae).Response /Remission\nNoresponse/noremission/recurrence- Ileo-cecal: Budesonide%\n- Mesalazine(> 2..4 g/day)  \nasalternative  optionModerate toseveredisease Patientswith\nhigh riskfor\ndisease\nprogression#\nIfindicated,  in \nselectedpatients:\nNomedicationMaintain\nremissionwith\nAZA/6-MP/  \nMTXSteroid-dependent:\nTaperingofsteroidswithin16 \nweeksimpossibleorrecurrence\nwithin12 weeksafter stopping\nsteroidsSteroid-refractory:  \nActivediseasedespiteoral \ncorticosteroidsduring4weeks\nSurgerytobe\ndiscussed\n(especiallyin \nlocalizedileo-\ncecaldisease)Anti-Integrin\nVedolizumab\n(preferin elder-\nlies and/orhx\nofmalignancy)Anti-TNF&\n+/\u2013\nAZA/6-MP/ MTX \n(preferCombo-therapy, \nifpossible)\nInsufficientresponse\norlossofresponseIntoleranceor\nprimarynon response\n1.Optimizebyescalation(dose escalation\nor/andintervalreduction)\n2.Add AZA/6-MP, ifCombo possibleChange tootheranti-\nTNF&ortoother\nclassofbiologicals3. Change tootherclass\nofbiologicalsSurgerytobe\nevaluatedMaintain\nremissionwith\nselectedagentAssessment ofresponseafter 2 weeks; Tapering\nofcorticosteroids\nAssessment ofresponse\nevery10\u201312weeks\nAssessment ofresponse\nevery10-12 weeksAssessment ofresponseevery10-12 weeks(symptoms, calprotectinandUS) \n+ Antibiotics, \nifindicated\nAnti-TNFfirstchoice, especiallyifEIM presentand/or\nfasterresponsenecessary\nAnti-IL12/23\nUstekinumab\n(preferin selected\ncaseswithco-\nexistent psoriasis)In general: secondchoiceSystemiccorticosteroids\n+/\u2013\nAZA/6-MP/MTXMild diseaseEndoluminaler  M. Crohn: Therapie -Algorithmus  \nAZA Azathioprine  \nEIM Extra -intestinal   \n manifestations  \nIL Interleukin   \n6-MP 6-mercaptopurin   \nMTX   Methotrexate  \nTNF Tumour  necrosis  factor  \nUS Ultrasonography   Algorithm1: EndoluminalCD(withoutfistula)12,21,27,28,30-34\n% Budesonide:  CortimentMMX  isnot approvedfortreatmentofCD\n# See Table 1  (Indicatorsforseveredisease/ diseaseprogression)\n&Anti-TNF: Tumor-necrosis-factoralphaantibodies: Infliximabanditsbiosimilars(Remicade\u00ae/Inflectra\u00ae/Remsima\u00ae); Adalimumab(Humira\u00ae/Hyrimoz\u00ae); \nCertolizumabPeglol(Cimzia\u00ae).Response /Remission\nNoresponse/noremission/recurrence- Ileo-cecal: Budesonide%\n- Mesalazine(> 2..4 g/day)  \nasalternative  optionModerate toseveredisease Patientswith\nhigh riskfor\ndisease\nprogression#\nIfindicated,  in \nselectedpatients:\nNomedicationMaintain\nremissionwith\nAZA/6-MP/  \nMTXSteroid-dependent:\nTaperingofsteroidswithin16 \nweeksimpossibleorrecurrence\nwithin12 weeksafter stopping\nsteroidsSteroid-refractory:  \nActivediseasedespiteoral \ncorticosteroidsduring4weeks\nSurgerytobe\ndiscussed\n(especiallyin \nlocalizedileo-\ncecaldisease)Anti-Integrin\nVedolizumab\n(preferin elder-\nlies and/orhx\nofmalignancy)Anti-TNF&\n+/\u2013\nAZA/6-MP/ MTX \n(preferCombo-therapy, \nifpossible)\nInsufficientresponse\norlossofresponseIntoleranceor\nprimarynon response\n1.Optimizebyescalation(dose escalation\nor/andintervalreduction)\n2.Add AZA/6-MP, ifCombo possibleChange tootheranti-\nTNF&ortoother\nclassofbiologicals3. Change tootherclass\nofbiologicalsSurgerytobe\nevaluatedMaintain\nremissionwith\nselectedagentAssessment ofresponseafter 2 weeks; Tapering\nofcorticosteroids\nAssessment ofresponse\nevery10\u201312weeks\nAssessment ofresponse\nevery10-12 weeksAssessment ofresponseevery10-12 weeks(symptoms, calprotectinandUS) \n+ Antibiotics, \nifindicated\nAnti-TNFfirstchoice, especiallyifEIM presentand/or\nfasterresponsenecessary\nAnti-IL12/23\nUstekinumab\n(preferin selected\ncaseswithco-\nexistent psoriasis)In general: secondchoiceSystemiccorticosteroids\n+/\u2013\nAZA/6-MP/MTXMild disease\nAZA Azathioprine  \nEIM Extra -intestinal   \n manifestations  \nIL Interleukin   \n6-MP 6-mercaptopurin   \nMTX   Methotrexate  \nTNF Tumour  necrosis  factor  \nUS Ultrasonography   Endoluminaler  M. Crohn: Therapie -Algorithmus  Torres J et al. Lancet 2017  Targets und Mechanismen der verschiedenen Medikamente  Medikament\u00f6se \nTherapie  Krankheits -\nprogression  \n Therapie - \nkonzept  \nHeraus - \nforderungen   \nTherapie -\nAlgorithmus  \n(endo -\nluminal )  Vedolizumab  \nund \nUstekinumab  Emerging \ntherapies  Postoperative  \nTherapie  Take home   \nmessages  18 \u03b14\u03b27  darm -selektiv  TNF-\u03b1: systemisches proinflammatorisches  Zytokin  Darmlumen  \nEpithelium  \nLamina Propria  \nAktivierter  \nMakrophage  TNF-\u03b1 \nMAdCAM -1 \n\u03b14\u03b27 -Integrin  \nAktivierter  Lymphozyt  VDZ ADA  \nTNF-\u03b1 R NF-\u03baB \nBlutgef\u00e4ss  Mode of Action: Vedolizumab  (VDZ) ( Entyvio \u00ae) \nTNF: Tumornekrosefaktor; TNFR: Tumornekrosefaktor -Rezeptor; NF-\u03baB: nuclear factor 'kappa -light -chain -enhancer'    \n \nwww.swissmedicinfo.ch  ; Pedersen et al, 2014.  \n MAdCAM -1: mucosal addressin  cell adhesion molecule 1.  Sartor RB. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390 -407. Shih DQ, et al. Curr Gastroenterol Rep. 2009;11:473 -480. Sewell  GW, et al. Curr Opin Immunol. 2009;21:506 -513. \nKoizumi M, et al. Gastroenterology. 1992;103:840 -847. Bardin N, et al. In\ufb02amm Bowel Dis. 2006;12:16 -21. TNF\u03b1, tumor necrosis factor alpha.  \nProinflammatory cytokine release  \n(eg, TNF\u03b1, interleukins)  \nDisrupted protective  \nmucus layer  \nDendritic  cells sample luminal \nbacteria  \nIncrease in adhesion molecules  \nIncrease in vascular permeability  Dendritic cells  \npresent antigen  Mode of Action: Vedolizumab  (VDZ) ( Entyvio \u00ae) MAdCAM -1 \u03b14\u03b27 \nintegrin  MAdCAM -1 \nLymphocyte  \nIntegrins  \nMAdCAM -1, mucosal addressin cell adhesion molecule 1.  \nBriskin M, et al. Am J Pathol. 1997;151:97 -110.  \u03b14\u03b27 integrin/MAdCAM -1 Adh\u00e4sion  VDZ, vedolizumab.  \nSoler D, et al. J Pharmacol Exp Ther. 2009;330:864 -875.  \nBlood vessel  Gut submucosa  \nLymphocyte  \n\u03b14\u03b27 \nintegrin  Vedolizumab  Clinical remission: CDAI score of \u2264150 points.  \n*IS but not anti -TNF\u03b1 therapy.  \nCD, Crohn\u2019s disease; CDAI, Crohn\u2019s Disease Activity Index; CI, confidence interval; CS, corticosteroid; IS, immunosuppressive ; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 \nweeks; TNF\u03b1, tumor necrosis factor alpha; VDZ, vedolizumab.  \nHanauer SB, et al. Gastroenterology. 2013;144(suppl 1):S -772. Abstract Tu1138.  PBO  \nVDZ \nStudienergebnisse Vedolizumab  (VDZ) (GEMINI 2)  Hanauer SB, et al. Gastroenterology. 2013;144(suppl 1):S -772. Abstract Tu1138.  VDZ/PBO \nVDZ Q8W  \nVDZ Q4W  \n010203040506070\nOverall CS only IS* Anti-TNF\u03b1 30.1  43.5  45.5  \n28.0  60.0  \n54.5  \n46.9  60.4  \n51.9  \n20.5  29.3  37.7  P=0.0132  P=0.005  \n13.4 (2.8 -24.0)  13.5 ( \u20136.2-33.1)  32.0 (4.2 -59.8)  \n15.3 (4.6 -26.0)  4.9 ( \u201314.4 -24.2)  26.5 ( \u20130.7-53.8)  8.8 ( \u20134.6-22.1)  \n17.1 (3.1 -31.2)  CDAI -100 response at week 52  \nType of prior treatment failure  Patients, %  \n\uf044% (95% CI)                \nQ8W vs. PBO   \nQ4W vs. PBO  n=153  n=154  n=154  n=25  n=20  n=22  n=49  n=48  n=54  n=78  n=82  n=77  \nCDAI -100 response: (enhanced clinical response) \u2265100 -point decrease in the CDAI score.  \n*IS but not anti -TNF\u03b1 therapy.  \nCD, Crohn\u2019s disease; CDAI, Crohn\u2019s Disease Activity Index; CI, confidence interval; CS, corticosteroid; IS, immunosuppressive ; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 \nweeks; TNF\u03b1, tumor necrosis factor alpha; VDZ, vedolizumab.  Studienergebnisse Vedolizumab  (VDZ) (GEMINI 2)  Retrospective Analysis of Safety of Vedolizumab in \nPatients With Inflammatory Bowel Diseases  \nMeserve J, Aniwan S, Koliani -Pace JL et al .Clin Gastroenterol Hepatol . 2018 Sep 27. pii: \nS1542 -3565(18)31026 -7. doi: 10.1016/j.cgh.2018.09.035. [ Epub  ahead of print]  CD, Crohn\u2019s disease; IM, immunomodulator; IQR, interquartile range; TNFa , tumor necrosis factor alpha; VDZ, vedolizumab; y, years.  \nMeserve J, et al. Clin Gastroenterol and Hepatol . 2018. https://doi.org/10.1016/j.cgh.2018.09.035.   \nVICTORY  Variable Patients (N=1087)  \nCD, n (%)  650 (60)  \nDisease duration,  y, median (IQR)  9 (4-16) \nStricturing/penetrating  complication history, n/n (%)  439/650 (40)  \nFistulizing disease history, n/n (%)  237/650 (22)  \nPrior TNFa antagonist exposure, n (%)  884 (81)  \nConcomitant  corticosteroids, n (%)  536 (49)  \nConcomitant  IM, n (%)  417 (38)  \nConcomitant corticosteroids and IM, n (%)  214 (20)  \nVDZ exposure, days,  median  (IQR ) 264 (146 -413)  Victory : Mehrheitlich vorbehandelte Patienten mit schwerem Verlauf  Disease phenotype included stricturing or penetrating complication history for CD, disease extent for UC. Bold text indicates \nsignificance.  \nCD, Crohn\u2019s disease; CI, confidence interval; IBD, inflammatory bowel disease; IM, immunomodulator; N/A, not available; OR, o dds \nratio; SAE, serious adverse event; SI, serious infection; TNF, tumor necrosis factor; VDZ, vedolizumab.  \n1. Lukin  D, et al. DOP009. J Crohns  Colitis. 2018;12(suppl 1):S036. 2. Lukin  D, et al. 277. Gastroenterology. 2018;154( suppl  1):S68.  6.9 7.1 10.1  13.1  \n0510152025\nSI SAERate of event, %  \nOR 0.67,  \n95% CI 0.41 -1.07  OR 0.51,  \n95% CI 0.32 -0.81  VDZ (n=436)  TNF-antagonist (n=436)  \nSI SAE Safety profile by treatment  \nVICTORY  Schwere Infektionen und SAEs seltener unter VDZ als unter anti -TNF Disease phenotype included stricturing or penetrating complication history for CD, disease extent for UC. Bold text indicates \nsignificance.  \nCD, Crohn\u2019s disease; CI, confidence interval; IBD, inflammatory bowel disease; IM, immunomodulator; N/A, not available; OR, o dds \nratio; SAE, serious adverse event; SI, serious infection; TNF, tumor necrosis factor; VDZ, vedolizumab.  \n1. Lukin  D, et al. DOP009. J Crohns  Colitis. 2018;12(suppl 1):S036. 2. Lukin  D, et al. 277. Gastroenterology. 2018;154( suppl  1):S68.  6.9 7.1 10.1  13.1  \n0510152025\nSI SAERate of event, %  \nOR 0.67,  \n95% CI 0.41 -1.07  OR 0.51,  \n95% CI 0.32 -0.81  VDZ (n=436)  TNF-antagonist (n=436)  \nSI SAE Safety profile by treatment  Safety profile by treatment combinations  \nBiologic monotherapy (n=247)  \n6.8 9.1 9.3 12.7  14 \n0510152025\nSI SAERate of event, %  Biologic + steroids or IM (n=N/A)  \nBiologic + steroids and IM (n=137)  \n8.0 14.0  \nVICTORY  Schwere Infektionen und SAEs seltener unter VDZ als unter anti -TNF 4.1 4.7 10.1  14.5  \n0510152025\nSI SAEVDZ TNF-antagonistRate of events, %  Safety profile: biologic monotherapy1,2 \n(n=247; VDZ=142)  \nSI 11.5  14.0  13.9  14.0  \n0510152025\nSI SAEVDZ TNF-antagonistRate of events, %  Safety profile: biologic + steroids and IM1,2  \n(n=137; VDZ=69)  \nOR 0.37,  \n95% CI 0.13 -1.02  OR 0.29,  \n95% CI 0.12 -0.73  OR 0.81,  \n95% CI 0.31 -2.07  OR 0.66,  \n95% CI 0.27 -1.65  SAE SI SAE \nVICTORY  \nDisease phenotype included stricturing or penetrating complication history for CD, disease extent for UC. Bold text indicates \nsignificance.  \nCD, Crohn\u2019s disease; CI, confidence interval; IBD, inflammatory bowel disease; IM, immunomodulator; N/A, not available; OR, o dds \nratio; SAE, serious adverse event; SI, serious infection; TNF, tumor necrosis factor; VDZ, vedolizumab.  \n1. Lukin  D, et al. DOP009. J Crohns  Colitis. 2018;12(suppl 1):S036. 2. Lukin  D, et al. 277. Gastroenterology. 2018;154( suppl  1):S68.  Sicherheitsprofil durch Kombi -Therapie ung\u00fcnstig beeinflusst  Stand: Januar 2019  TNF\u03b1  \nIFN\u03b3  \nIL-12 \nAktivierte DC  \nTh1 \n31 Vereinfachte Darstellung  \nDC: Dendritische Zelle; IFN: Interferon; IL: Interleukin; Th: T-Helferzelle; TNF: Tumornekrosefaktor  1. Cytokines in inflammatory bowel disease.  \n    Neurath  MF. Nat Rev Immunol . 2014 May; 14(5):329 -42 \n \n IL-12 /23: Schl\u00fcsselzytokine  in der Entz\u00fcndungskaskade bei M. Crohn  Stand: Januar 2019  \nIL-23 \nIL-17A/F  IL-22 \nTNF\u03b1  Th17  \nTNF\u03b1  \nIFN\u03b3  \nIL-12 \nAktivierte DC  \nTh1 \n32 Vereinfachte Darstellung  \nDC: Dendritische Zelle; IFN: Interferon; IL: Interleukin; Th: T-Helferzelle; TNF: Tumornekrosefaktor  1. Cytokines in inflammatory bowel disease.  \n    Neurath  MF. Nat Rev Immunol . 2014 May; 14(5):329 -42 \n2. IL-23: a master regulator in Crohn disease  \n    Neurath  MF. Nat Med. 2007;13:26 \u20138 IL-12 /23: Schl\u00fcsselzytokine  in der Entz\u00fcndungskaskade bei M. Crohn  Stand: Januar 2019  \n3\n3 \nVereinfachte Darstellung  \nIL: Interleukin; NK: Nat\u00fcrliche Killerzelle  IL-12 IL-23 \n33 IL-12 und IL -23 aktivieren T - oder NK -Zellen  Stand: Januar 2019  \nIL-12 IL-23 3\n4 \n34 Mode of Action: Ustekinumab  (Stelara \u00ae) \nVereinfachte Darstellung  \nIL: Interleukin; NK: Nat\u00fcrliche Killerzelle  Inhibierung der Differenzierung zu  \nTh1 Effektorzellen  durch Blockade der  \nIL-12/IL -12 Rezeptor Interaktion  MESENTERIC  \nLYMPH NODE  \nNaive T  Zelle  IL-12  \nRezeptor  \naktivierte DC  \n(APC)  \nAnti-p40 \nUstekinumab  \n IL-12  p40  \np35  \nInhibierte Differenzierung  \nzu Th1 Zellen  IL-12  \n \nIFN\u03b3 \nTh1 Zelle  \nS1PR \n\u03b14\u00df7 \nIL-12R \nNeurath MF. Cytokines in inflammatory bowel disease.  Nat Rev Immunol 2014;14:329 -342.  \nNeurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol  Hepatol  2017;14:269 -278.  Antigen Presentation  \nKostimulation  \nCytokine  Sekretion  Mode of Action: Ustekinumab  (Stelara \u00ae) MESENTERIC  \nLYMPH NODE  \nNaive T  Zelle  \naktivierte DC  \n(APC)  \nIL-23  \np40  \np19  Anti-p40 \nUstekinumab  \nTh17  Zelle  \nS1PR \n\u03b14\u00df7 \nIL-6, TGF-\uf0621 \nIL-21, IL -1 \uf062  \nIL-23 \nRezeptor  \nInhibierung der  \nTh17 Zell Aktivierung  Anti-p19 \nGuselkumab  \nRisankizumab  \nMirikizumab  \nPTG200  \nAntigen Pr\u00e4sentation  \nKostimulation  \nCytokine  Sekretion  Inhibierung der Differenzierung zu  \nTh17 Effektorzellen  durch Blockade der  \nIL-23/IL -23 Rezeptor Interaktion  Mode of Action: Ustekinumab  (Stelara \u00ae) \nNeurath MF. Cytokines in inflammatory bowel disease.  Nat Rev Immunol 2014;14:329 -342.  \nNeurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:269 -278.  Stand: Januar 2019  37 \nBitte beachten Sie die Ausf\u00fchrungen in der Fachinformation  \nwww.swissmedicinfo.ch, Stand Januar 2019, abgerufen am 12.01.2018  Ustekinumab  (Stelara \u00ae): Verabreichung  Stand: Januar 2019  38 \nBitte beachten Sie die Ausf\u00fchrungen in der Fachinformation  \nwww.swissmedicinfo.ch, Stand Januar 2019, abgerufen am 12.01.2018  Ustekinumab  (Stelara \u00ae): Verabreichung  Stand: Januar 2019  39 \nBitte beachten Sie die Ausf\u00fchrungen in der Fachinformation  \nwww.swissmedicinfo.ch, Stand Januar 2019, abgerufen am 12.01.2018  Ustekinumab  (Stelara \u00ae): Verabreichung  Stand: Januar 2019  40 UNITI -1:  \nNach Versagen von  \nAnti-TNF\u03b1 -Therapie  \nUNITI -2:  \nNach Versagen einer konventionellen \nTherapie  IM-UNITI:  \nResponder * aus  \nUNITI -1 und UNITI -2 \n*Responder: CDAI -100-Ansprechen (R\u00fcckgang des CDAI um 100 oder mehr Punkte) oder CDAI < 150 in Woche 8  Ustekinumab  as Induction and Maintenance  \nTherapy for Crohn's Disease.    \nFeagan BG et al. N Engl  J Med 2016;375:1946 -60 Zulassungsstudien Ustekinumab  bei M. Crohn  Stand: Januar 2019  PE: Prim\u00e4rer  Endpunkt ; q8w: alle 8 Wochen ; q12w: alle 12 Wochen  \n*Responder: CDAI -100-Ansprechen ( R\u00fcckgang des CDAI um 100 oder mehr Punkte) oder CDAI < 150  \n41 IM-UNITI Erhaltung -Studie :  \nFollow -up von UNITI -1 und UNITI -2 \nUstekinumab  as Induction and Maintenance  \nTherapy for Crohn's Disease.    \nFeagan BG et al. N Engl  J Med 2016;375:1946 -60 Stand: Januar 2019  010203040506070\n0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152\nPlacebo (n=131) Ustekinumab  90 mg q8w (n=128) Ustekinumab  90 mg q12w (n=129)45,0% 46.9% 42 Anteil der Patienten [%]  \nWochen der Erhaltungsphase  \n(Woche 44 \u2259 Woche 52 nach Induktion)  \n*CDAI <150  \nIntention -to-Treat -Analyse  \nBei allen Patienten, einschlie\u00dflich der Placebo -Gruppe, war eine \nStandardmedikation m\u00f6glich  \nq8w: alle 8 Wochen, q12w: alle 12 Wochen  \n IM-UNITI  IM-UNITI LTE  \n35,9%  \n42 Remission IM -UNITI / IM -UNITI Longterm -extension trial \n48,8%  53,1%  \n38.0% 43.0% \n \nSandborn  W, et al. Efficacy and Safety of Ustekinumab for Crohn\u2019s Disease: \nResults from IM -UNITI Long -term Extension through 3 Years. UEGW 2018.  Stand: Januar 2019  0102030405060708090\n0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152\nPlacebo (n=51) Ustekinumab  90 mg q8w (n=52) Ustekinumab  90mg q12w (n=53)54,7%  55,8%  43 Anteil der Patienten [%]  \nWochen der Erhaltungsphase  \n(Woche 44 \u2259 Woche 52 nach Induktion)  \n*CDAI <150  \nIntention -to-Treat -Analyse  \nBei allen Patienten, einschlie\u00dflich der Placebo -Gruppe, war eine \nStandardmedikation m\u00f6glich  \nq8w: alle 8 Wochen, q12w: alle 12 Wochen  \n IM-UNITI  IM-UNITI LTE  \n49,0%  \n43 56,6%  65,4%  \n50,8%  \n 53,8%  \n \nSandborn  W, et al. Efficacy and Safety of Ustekinumab for Crohn\u2019s \nDisease: Results from IM -UNITI Long -term Extension through 3 \nYears. UEGW 2018.  Subgruppe: TNF-na\u00efv  Remission IM -UNITI / IM -UNITI Longterm -extension trial Medikament\u00f6se \nTherapie  Krankheits -\nprogression  \n Therapie - \nkonzept  \nHeraus - \nforderungen   \nTherapie -\nAlgorithmus  \n(endo -\nluminal )  Vedolizumab  \nund \nUstekinumab  Emerging \ntherapies  Postoperative  \nTherapie  Take home   \nmessages  \nSphingosin -1-phosphat  \nRezeptor -modulator  \n(Ozanimod ) \n \nJAK 1 -Inhibitor \n(Upadacitinib ) \n \nIL-23 AK ( Risankizumab , \nMirikizumab ) \n \n   Afferent  \nlymphatics  Afferent  \nlymphatics  \nEfferent lymphatics  Sphingosin -1-P receptor  \n1 2 3 4 5 \nFingolimod  \nOzanimod  \nEtrasimod  Emerging therapies  \nLymphocyte  \u201etrapping \u201c by sphingosin -1-phosphate receptor  modulators  \nCourtesy  of PD Dr. Misselwitz ( submitted  to Digestion 2019)  S1P \nS1P1 S1P2 S1P3 S1P4 S1P5 \nLymphocytes,  \ndendritic cells  Leukocytes,  \ndendritic cells  NK cells  \nEndothelial  cells , \ncardiac cells,  \nneurons  Vascular s mooth  muscle \ncells,  endothelial  cells, \ncardiac cells, lung \nfibroblasts, tumour cells  Vascular s mooth  muscle \ncells,  endothelial  cells, \ncardiac cells, lung \nfibroblasts  Breast cancer cells  Endothelial  cells, \noligodendrocytes  Distribution1 Immune \ncells  \nNon -\nimmune \ncells  Ozanimod   Ozanimod   \nNK cell, natural killer cell; S1P , sphingosine -1-phosphate; S1Pn, sphingosine -1\u2010phosphate receptor n.  \n1. Peyrin -Biroulet  L, et al. Autoimmun  Rev 2017;16:495 \u2013503; 2 . Blaho  V, et al. J Lipid Res 2014;55:1596 \u20131608; 3. Takuwa  N, et al. Cardiovasc Res 2010;85:484 \u2013493.  S1P Rezeptor -Subtypexpression  Lymphoid tissue  Blood  Gut Tissue  \n Lymphoid tissue  Blood  Inflamed  \nGut Tissue  \nS1P \n S1P receptor \nLymphocytes providing  \nimmune surveillance \nLymphocytes circulating  \nthrough tissue \nEffector  \nT cell \nAntigen \nEncounter  \nS1P1 regulator \nS1P1  \nregulator  \nAntigen Encounter  \nX \nS1P gradient  S1P gradient  \nS1P = sphingosine 1 -phosphate.  \nAoki et al. Mediators Inflamm . 2016  S1P Regulation: Lymphozyten trapping  YELLOWSTONE:  Phase 3 CD Programm   \nOzanimod 1 mg QD  Nonresponder  Disease relapse  End of maintenance  \nOPEN -LABEL EXTENSION  RPC01 -3204  Placebo QD (n=200 \u00d7 2) RPC01 -3201/3202 (2 Studies)  \nOzanimod 1 mg QDa (n=400)  INDUCTION  \n12 Weeks  \nPlacebo QD (n=200)  RPC01 -3203  \nMAINTENANCE  \n40 Weeks  \nOzanimod 1 mg QD  \nPlacebo QD  1:1 Placebo QD  Responder  \naOzanimod  HCl 1 mg equals ozanimod 0.92 mg.  \nQD = once daily.  \u2022Aged 18 -75 years  \n\u2022Active moderate to severe CD  \n\u2022CDAI \u2265220 and \u2264450  \n\u2022Average daily SF score of \u22654 points and/or an AP score of \u22652 points  \n\u2022Effective method of contraception for women of childbearing potential + condom for male partners  \n\u2022Failure of or intolerance to CSs, immunomodulators, or biologics, including:  \nCSs \n\u2022Oral prednisone \u226530 mg/d  \n\u2022Budesonide \u22659 mg/d  \n\u2022Beclomethasone \u22655 mg/d or equivalent \nfor  \n>2 weeks  \n\u2022An equivalent (to oral prednisone) of IV \nCSs for  \n1 week  \n\u20222 failed attempts to taper below 10 mg  Immunomodulators  \n\u2022Azathioprine \u22651.5 mg/kg/d PO for >8 weeks  \n\u20226-Mercaptopurine \u22650.75 mg/kg/d PO for >8 \nweeks  \n\u2022Methotrexate \u226512.5 mg/wk SC or IM for >8 \nweeks  Biologics  \n\u2022Ustekinumab 260 mg IV at week 0 + 90 mg SC \nat week 8  \n\u2022Vedolizumab 300 mg IV at weeks 0, 2, and 6  \n\u2022Adalimumab 80 mg SC at week 0 + 40 mg SC \nat week 2  \n\u2022Infliximab 5 mg/kg IV at weeks 0, 2, and 6  \nCS = corticosteroid; IV = intravenously; PO = orally; SC = subcutaneously; IM = intramuscularly.  Einschlusskriterien  Ozanimod -Studie  Risankizumab  und Upadacitinib  in der Entwicklung \nf\u00fcr die Behandlung des Morbus Crohn  \nModifiziert nach: Pedersen J. et al., World J Gastroenterol  2014; 20(1):64 -77 JAK2  JAK3  \n TYK2  \n JAK1  \n4 Mitglieder der JAK -Familie, zwar strukturell \u00e4hnlich, aber kleine Unterschiede in der \nStruktur ihrer ATP-Bindungstasche  \nO'Shea JJ et al. Ann Rev Med 2015;66:311 \u201328 Die JAK -Familie  aIL-10/IL -22 may have pro - or anti -inflammatory activities depending on the cellular environment and/or \ndisease state  \nbType II cytokine receptors such as those for gp130 subunit sharing receptors for IL -6 and IL -11 as well as IL -10, \nIL-19, IL -20, and IL -22, mainly signal through JAK1, but also associate with JAK2 and TYK2  \nEPO, erythropoietin; GM -CSF, granuloctye macrophage colony -stimulating factor; IFN, interferon; TPO, \nthrombopoietin; TYK2, tyrosine kinase 2  \u2022Growth/maturation \nof lymphoid cells  \n\u2022Differentiation/  \nhomeostasis of  \nT cells, NK cells  \n\u2022B-cell class switching  \n\u2022Inflammation  \u2022Antiviral  \n\u2022Inflammation  \n\u2022Antitumor  \u2022Na\u00efve T -cell \ndifferentiation  \n\u2022T-cell homeostasis  \n\u2022Inflammation  \n\u2022Granulopoiesis  \u2022Antiviral  \n\u2022Inflammation  \n\u2022Antimycobacterial  \u2022Innate immunity  \n\u2022Differentiation/  \nproliferation of \nTh17 cells  \n\u2022Inflammation  \u2022Erythropoiesis  \n\u2022Myelopoiesis  \n\u2022Megakaryocyte/  \nplatelet \nproduction  \n\u2022Growth  \n\u2022Mammary \ndevelopment  \nJAK1  \n JAK3  \n JAK2b \nTYK2  \n JAK1  \n JAK1  \nTYK2b \nJAK1  \n JAK2 \nJAK2 \nTYK2b \n JAK2 \nJAK2 \u03b3-chain cytokines \nIL-2, IL-4, \n IL-7, IL-9, \nIL-15, IL -21 IFN-\u03b3 IL-12 \nIL-23 EPO,TPO  \nGM-CSF \nIL-3, IL-5 IL-6, IL-11, \nIL-13, IL -27, \nIL-31, IL -25 Type 1 IFNs  \n (IFN-a/\uf062) \n IL-10a  \nIL-22 \nFigure adapted from: Clark et al, J Med Chem 2014;57:5023 -5038. O\u2019Shea JJ, et al. Annu \nRev Med 2015;66:311 \u201328; Schwartz DM, et al. Nat Rev Rheumatol 2016;12:25 \u201336; \nGhoreschi  K, et al. Immunol Rev 2009;228:273 \u201387; Sanjabi  S, et al. Curr Opin Pharmacol \n2009;9:447 \u201353; Guschin  D et al. EMBO J. 1995;14:1421 \u20139; Ivanshkiv  LB and Donlin  LT. \nNat Rev Immunol  2014; 14(1):36 -49; Adachi K, Davis M. Proc Natl Acad  Sci USA \n2011;108:1549 \u201354.  Verschiedene  Zytokin -Rezeptoren  verwenden  verschiedene  JAK-Paarungen   Patel M, et al. Dermatol  Ther . 2012; Sofen  H, et al. J Allergy Clin Immunol . 2014  \nIL-23R IL-12R\u03b21 Risankizumab  \np19 p40 IL-23 \nIL-12R\u03b21 \n IL-12R\u03b22 \np40 p35 IL-12 \nTH1 pathway  TH17 pathway  Risankizumab : Selektiver  IL23 (p19) Rezeptor -Blocker (TH 17 pathway)  \nAktuell Phase 3 Studien  \ni.v. Induktion, dann s.c.  \nNebenwirkungsprofil vergleichbar mit  \nPlacebo (Phase 2b)  Postoperatives setting  \n\u00a9Michael Sulz  Sulz MC, et al. submitted  to Digestion (Nov 2019)  Postoperatives setting  Medikament\u00f6se \nTherapie  Krankheits -\nprogression  \n Therapie - \nkonzept  \nHeraus - \nforderungen   \nTherapie -\nAlgorithmus  \n(endo -\nluminal )  Vedolizumab  \nund \nUstekinumab  Emerging \ntherapies  Postoperative  \nTherapie  Take home   \nmessages  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}